{ "meta": { "data_length": 1, "message": "Statements retrieved successfully", "request_url": "http://api.moalmanac.org/statements?agent_id=agent%3Aorg%3Afda&proposition_id=prop%3Avtxr%3A422", "status": "success", "status_code": 200, "timestamp_elapsed": 0.004262, "timestamp_received": "2026-09-25T01:17:00.037843+00:00Z", "timestamp_returned": "2026-09-25T01:17:00.042105+00:00Z", "trace_id": "90e65d4f-d125-4d14-b52f-941e302ba547" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://dev.moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:fda:enhertu:2:0", "type": "Statement", "description": "The U.S. Food and Drug Administration granted accelerated approval to trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy. The product label states that these indications are approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2022-08-11:0", "type": "Contribution", "description": "Indication received accelerated approval.", "date": "2022-08-11", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:enhertu", "type": "Document", "documentType": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [package insert]. FDA.", "title": null, "aliases": [], "description": "Daiichi Sankyo, Inc. Enhertu (trastuzumab deruxtecan) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761139s038s042lbl.pdf. Revised December 2025. Accessed December 24, 2025.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761139s038s042lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761139" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Daiichi Sankyo, Inc.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Enhertu", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "trastuzumab deruxtecan", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2019-12-20", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 761139, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-12-15", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:422", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:oncotree:NSCLC", "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "mappings": [], "extensions": [ { "name": "solid_tumor", "value": true, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC" ] } }, "objectTherapeutic": { "id": "tx:ncit:C128799", "conceptType": "Therapy", "name": "Trastuzumab deruxtecan", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:2267582", "code": "2267582", "name": "trastuzumab deruxtecan", "system": "RxNorm", "systemVersion": "20250602", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2267582" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:3666979", "code": "3666979", "name": "Trastuzumab deruxtecan", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/3666979" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:838469001", "code": "838469001", "name": "Trastuzumab deruxtecan", "system": "SNOMED", "systemVersion": "2026-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=838469001&edition=MAIN/2026-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:37498192", "code": "37498192", "name": "trastuzumab deruxtecan", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/37498192" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "HER2 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C128799", "code": "C128799", "name": "Trastuzumab Deruxtecan", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C128799" ] } }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:23", "present": true, "subject": { "id": "bmkr:23", "type": "CategoricalVariant", "name": "ERBB2 activating variants", "constraints": [ { "type": "DefiningLocationConstraint", "location": { "id": "ga4gh:SL.tZDv33gDtUO9Ow5G83xXdvKSwKVkBPkq", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Sequence spanning the length of refseq:NP_004439.2, the protein product of the MANE Select coding transcript for ERBB2 (refseq:NM_004448.4).", "digest": "tZDv33gDtUO9Ow5G83xXdvKSwKVkBPkq", "sequenceReference": { "id": "ga4gh:SQ.AF1UFydIo02-bMplonKSfxlWY2q6ze3m", "type": "SequenceReference", "name": "NP_004439.2", "aliases": [ "ensembl:ENSP00000269571.4", "ga4gh:SQ.AF1UFydIo02-bMplonKSfxlWY2q6ze3m", "refseq:NP_004439.2" ], "description": "The protein product of the MANE Select coding transcript for ERBB2 (refseq:NM_004448.4), corresponding to the Refseq protein accession NP_004439.2.", "moleculeType": "protein", "refgetAccession": "SQ.AF1UFydIo02-bMplonKSfxlWY2q6ze3m", "residueAlphabet": "aa" }, "start": 0, "end": 1255, "sequence": null }, "relations": [], "matchCharacteristic": { "primaryCoding": { "code": "is_within", "system": "ga4gh-gks-term:location-match" } } }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:3430", "conceptType": "Gene", "name": "ERBB2", "primaryCoding": { "id": "coding:hgnc:3430", "code": "HGNC:3430", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000141736", "code": "ENSG00000141736", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000141736" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:2064", "code": "2064", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/2064" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_004448.4", "code": "NM_004448.4", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4" ] } } ] } }, { "type": "FunctionConstraint", "functionConsequence": { "id": "func:so:0002053", "name": "Gain-of-function", "primaryCoding": { "id": "coding:so:0002053", "code": "SO:0002053", "name": "gain_of_function_variant", "system": "https://www.ebi.ac.uk/ols4/ontologies/so", "iris": [ "https://www.ebi.ac.uk/ols4/ontologies/so/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FSO_0002053" ] } } } ], "extensions": [ { "name": "biomarker_type", "value": "Somatic variant" }, { "name": "chromosome", "value": "17" }, { "name": "start_position", "value": null }, { "name": "end_position", "value": null }, { "name": "reference_allele", "value": null }, { "name": "alternate_allele", "value": null }, { "name": "cdna_change", "value": null }, { "name": "protein_change", "value": null }, { "name": "variant_annotation", "value": null }, { "name": "exon", "value": null }, { "name": "rsid", "value": null }, { "name": "hgvsg", "value": null }, { "name": "hgvsc", "value": null }, { "name": "requires_oncogenic", "value": true } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:fda:enhertu:2", "type": "Indication", "description": "ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy. These indications are approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2022-08-11:0", "type": "Contribution", "description": "Indication received accelerated approval.", "date": "2022-08-11", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:enhertu", "type": "Document", "documentType": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [package insert]. FDA.", "title": null, "aliases": [], "description": "Daiichi Sankyo, Inc. Enhertu (trastuzumab deruxtecan) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761139s038s042lbl.pdf. Revised December 2025. Accessed December 24, 2025.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761139s038s042lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761139" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Daiichi Sankyo, Inc.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Enhertu", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "trastuzumab deruxtecan", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2019-12-20", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 761139, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-12-15", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Accelerated", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }